ArticleFrontiers in oncology2026
ORC6 marks a replication-active malignant epithelial state and is associated with immune-low features in oral squamous cell carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Oral squamous cell carcinoma (OSCC) shows marked biological heterogeneity, but markers that connect malignant epithelial states with the tumor immune context remain limited. Origin recognition complex subunit 6 (ORC6) participates in DNA replication licensing, but its disease-specific role in OSCC is not well defined. Methods: We integrated anatomically filtered bulk transcriptomic data, external validation cohorts, single-cell transcriptomic profiling, immune-context analyses, proliferation-adjusted sensitivity analyses, virtual perturbation, and in vitro ORC6-knockdown assays to evaluate the clinical and biological relevance of ORC6 in OSCC. Results: After reconstruction of a strictly defined TCGA oral cavity OSCC cohort excluding base of tongue and other non-oral cavity subsites, ORC6 remained upregulated in OSCC tissues and cell lines and was associated with adverse clinicopathological features and poorer survival. Exploratory analysis in the HPV-negative GSE41613 cohort further supported the adverse survival association of ORC6. Single-cell analysis showed preferential enrichment of ORC6 in malignant epithelial cells. Within this compartment, high ORC6 expression marked a replication-active state characterized by activation of DNA-replication and cell-cycle programs and weaker transcriptional signatures of interferon response and antigen presentation. These differences were directionally preserved in donor-matched pseudobulk comparisons and after cell-cycle-score regression. At the bulk-tumor level, proliferation-adjusted models showed that ORC6 retained directionally inverse associations with selected immune-related features, including cytolytic activity, IFN-γ response, and MHC-I/antigen-presentation signatures. ORC6 knockdown in CAL27 cells reduced cell growth, migration, invasion, and S-phase fraction while increasing antigen-presentation-associated transcripts and surface HLA-A/B/C expression. Discussion: These findings support ORC6 as a marker of a replication-active malignant epithelial state associated with attenuated immune-related features in OSCC, particularly antigen-presentation-related programs. Further functional immune-recognition studies and independent clinical validation are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.